Matinas BioPharma Holdings, Inc.

MTNB NYSE SEC CIK 1582554
Follow Matinas BioPharma Weekly email: filings, results, news

Financials

Reported figures only · latest: Q2 2026 USD · US GAAP
Net income −$1.3M +74.7% vs same quarter last year
EPS, diluted −$0.21 +79.6% vs same quarter last year
Operating cash flow −$1.8M +9.2% vs same quarter last year
Operating income −$1.6M +15.4% vs same quarter last year
Net income by quarter
−$4.3M
−$8.4M
−$1.7M
−$5.2M
−$1.5M
−$1.9M
−$1.9M
−$1.3M
Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income14 fiscal years
  • Revenue
  • Net income
−$30M−$20M−$10M$0$10MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25-−$10.3M
FY24-−$24.3M
FY23$1.1M−$22.9M
FY22$3.2M−$21M
FY21$33K−$23.3M
FY20$158.3K−$22.4M
FY19$89.8K−$17.4M
FY18$119.8K−$14.1M
FY17$149.7K−$15.5M
FY16$0−$7.6M
FY15$194.5K−$9.1M
FY14$0−$10.2M
FY13-−$3.7M
FY12--
MarginsShare of revenue
  • Operating margin
  • Net margin
−80000%−60000%−40000%−20000%0%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25--
FY24--
FY23−2168.4%−2093.2%
FY22−771.3%−658.6%
FY21−74954.5%−70554.5%
FY20−15288.4%−14177%
FY19−21067.4%−19343.4%
FY18−12230.9%−11760.4%
FY17−11024.6%−10345.9%
FY16--
FY15−5096%−4697%
FY14--
FY13--
FY12--
Free cash flowOperating cash flow minus capital expenditure
−$30M−$20M−$10M$0FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25-
FY24-
FY23−$15.5M
FY22−$20M
FY21−$15.5M
FY20−$17.4M
FY19−$14.5M
FY18−$10.9M
FY17−$12.4M
FY16−$6.1M
FY15−$7.9M
FY14−$8.2M
FY13−$3.1M
FY12-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Matinas BioPharma
  • Healthcare median
−80000%−60000%−40000%−20000%0%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearMatinas BioPharmaHealthcare median
FY25-−40.6%
FY24-−60.7%
FY23−2093.2%−97.1%
FY22−658.6%−128.5%
FY21−70554.5%−129.2%
FY20−14177%−136.5%
FY19−19343.4%−133.7%
FY18−11760.4%−173.4%
FY17−10345.9%−176.7%
FY16-−164.8%
FY15−4697%−183.4%
FY14-−133%
FY13-−88.5%
FY12-−87.4%

News

No stories filed under Matinas BioPharma yet - coverage appears here as the news feed clusters it.